Beginning Cash: The amount of cash reported by the company on its previous statement.
Altamira Therapeutics Ltd. (CYTOF) had Beginning Cash of $0.73M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-8.46M |
|
-- |
|
-- |
|
$6.85M |
|
$-6.85M |
|
$-1.61M |
|
$-8.46M |
|
$-8.46M |
|
$-8.46M |
|
$-8.46M |
|
$-8.46M |
|
$-8.46M |
|
$-6.85M |
|
$-6.72M |
|
2.83M |
|
2.83M |
|
$-2.99 |
|
$-2.99 |
|
| Balance Sheet Financials | |
$1.54M |
|
$0.10M |
|
$7.11M |
|
$8.65M |
|
$1.16M |
|
-- |
|
$0.92M |
|
$2.09M |
|
$6.57M |
|
$1.94M |
|
$6.57M |
|
4.66M |
|
| Cash Flow Statement Financials | |
$-6.11M |
|
$-0.12M |
|
$6.51M |
|
|
Beginning Cash |
$0.73M |
$1.00M |
|
$0.26M |
|
$0.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-128.83% |
|
-436.41% |
|
-97.75% |
|
-128.83% |
|
$1.41 |
|
$-2.20 |
|
$-2.16 |
|